CN106727620B - Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer - Google Patents
Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer Download PDFInfo
- Publication number
- CN106727620B CN106727620B CN201611096574.9A CN201611096574A CN106727620B CN 106727620 B CN106727620 B CN 106727620B CN 201611096574 A CN201611096574 A CN 201611096574A CN 106727620 B CN106727620 B CN 106727620B
- Authority
- CN
- China
- Prior art keywords
- ovarian cancer
- pyridoxal phosphate
- application
- treating ovarian
- plp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to application of pyridoxal phosphate in preparation of a medicament for treating ovarian cancer. Experiments prove that pyridoxal phosphate can inhibit the cell proliferation of ovarian cancer, has obvious inhibition effect, and can be used for preparing medicaments for treating ovarian cancer or preparing related reagents for researching the occurrence and development mechanism of ovarian cancer. The pyridoxal phosphate is an active form of vitamin B6, while vitamin B6 is a water-soluble vitamin which is relatively safe and nontoxic and has no side effect even if being applied in a large dose, so the pyridoxal phosphate has strong clinical application possibility in the aspect of treating ovarian cancer.
Description
Technical Field
The invention relates to the technical field of molecular biology and medicines, in particular to application of pyridoxal phosphate in preparation of a medicine for treating ovarian cancer.
Background
Pyridoxal phosphate (PLP, Pyridoxal 5' -phosphate monohydrate) is the active form of vitamin B6 and has the molecular formula:
PLP is a coenzyme of various enzymes, and participates in more than 140 catalytic reactions, such as metabolism of amino acids such as cysteine, synthesis of neurotransmitters such as catecholamine, and the like. At present, PLP is known to promote transaminase to transaminate and increase dopamine content in vivo, and is a medicament clinically used for treating Parkinson's disease. It has also been reported that PLP can be administered clinically to effectively treat neonatal epileptic encephalopathy. Chinese patent publication CN200880018228.6, published Japanese 2010.03.31, also discloses that pyridoxal 5' -phosphate can treat tardive dyskinesia by oral administration of 100-4000 mg/day, such as 100-750 mg/day or about 250 mg/day. However, the research on PLP in tumor is very little, and the research on PLP in ovarian cancer is not related. Further research and development of new uses of PLP would be beneficial to fully utilize the compound and facilitate the treatment of clinically relevant diseases.
Disclosure of Invention
The invention aims to provide a new application of pyridoxal phosphate aiming at the defects in the prior art.
In a first aspect of the invention there is provided the use of pyridoxal phosphate in the manufacture of a medicament for the treatment of ovarian cancer.
In a second aspect of the invention, there is provided the use of pyridoxal phosphate in the manufacture of an agent for inhibiting the proliferation of ovarian cancer cells.
The ovarian cancer cells are SK-OV-3 or OVCAR-3.
The invention has the advantages that:
experiments prove that the PLP can inhibit the proliferation of ovarian cancer cells, so that the PLP can be used for preparing a medicament for treating ovarian cancer or preparing a related reagent for researching the occurrence and development mechanism of ovarian cancer. In addition, during the research of the inventors of the present application, it was found that the inhibitory effect of PLP on the proliferation of ovarian cancer cells was much more significant than that of other substances.
It is known in the art that PLP is an active form of vitamin B6, whereas vitamin B6 is a water-soluble vitamin that is relatively safe and non-toxic even when administered in large doses, and thus PLP has strong clinical potential for use in the treatment of ovarian cancer.
Drawings
FIG. 1 results of experiments in which PLP inhibited ovarian cancer cell proliferation. A: SK-OV-3; b: OVCAR-3. Three independent experiments. Indicates P < 0.05.
Detailed Description
The following detailed description of the present invention will be made with reference to the accompanying drawings.
Example 1
1.PLP was purchased from sigma and formulated as a 50mg/ml stock solution with 1M HCl as specified.
2. PLP can inhibit proliferation of ovarian cancer cells
SK-OV-3(3000 cells/well) and OVCAR-3(5000 cells/well) were plated in 96-well plates and PLP (0.5mg/ml) was given for intervention 24 hours later, and the control group (HCl group) was given an equivalent amount of HCl. The proliferation efficiency was measured by the WST method, and the absorbance was measured by an enzyme-labeling instrument for OD450nm at 24 hours, 48 hours, and 72 hours, respectively. Prior to testing at each time point, the original medium was discarded, fresh serum-free medium was added, and 10. mu.l of WST-1 was added to each well, and the wells were returned to the incubator for further 2 hours. Referring to fig. 1, WST experiments showed that PLP significantly inhibited growth of ovarian cancer cell lines SK-OV-3 and OVCAR-3 at 48 hours and 72 hours (. P < 0.05).
The results indicate that the PLP can be used for preparing a medicament for treating ovarian cancer or preparing a related reagent for researching the occurrence and development mechanism of the ovarian cancer. In the research process of the inventor, the inhibition effect of PLP on the proliferation of ovarian cancer cells is found to be remarkably superior to that of other compounds.
The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.
Claims (3)
1. Application of pyridoxal phosphate in preparing medicine for treating ovarian cancer.
2. Use of pyridoxal phosphate in the preparation of a reagent for inhibiting ovarian cancer cell proliferation.
3. The use according to claim 2, wherein the ovarian cancer cells are SK-OV-3 or OVCAR-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611096574.9A CN106727620B (en) | 2016-12-01 | 2016-12-01 | Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611096574.9A CN106727620B (en) | 2016-12-01 | 2016-12-01 | Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN106727620A CN106727620A (en) | 2017-05-31 |
| CN106727620B true CN106727620B (en) | 2020-03-31 |
Family
ID=58884608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611096574.9A Active CN106727620B (en) | 2016-12-01 | 2016-12-01 | Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106727620B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112691103B (en) * | 2020-12-28 | 2022-07-26 | 重庆医科大学附属第一医院 | Application of pyridoxal in preparation of medicine for treating ovarian cancer |
| CN115531380A (en) * | 2022-09-19 | 2022-12-30 | 重庆医科大学附属第一医院 | Application of fluoropyridoxine in preparation of anti-cancer drugs |
-
2016
- 2016-12-01 CN CN201611096574.9A patent/CN106727620B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| DNA拓扑异构酶Ⅰ抑制剂在卵巢癌治疗中的应用;孙正怡等;《中华妇产科杂志》;19960630;第34卷(第6期);378-379 * |
| 磷酸吡哆醛对H22肝癌细胞DNA拓扑异构酶Ⅰ活性的影响;陈兴等;《河北省科学院学报》;20030831;第20卷(第3期);175-178 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106727620A (en) | 2017-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6938682B2 (en) | Antimitocin: a targeted inhibitor of mitochondrial biosynthesis to eradicate cancer stem cells | |
| CN106727620B (en) | Application of pyridoxal phosphate in preparation of medicine for treating ovarian cancer | |
| FI3347002T3 (en) | Treatment of alzheimer's disease in a particular patient population | |
| TW201412306A (en) | Prophylactic/therapeutic agent for influenza virus infection | |
| JP2022184941A (en) | Compositions containing decitabine, 5-azacitidine and tetrahydrouridine and uses thereof | |
| CN111956804B (en) | Novel use of inhibitors of OTUB1 | |
| CN113573736A (en) | Modified microRNAs and their use in the treatment of cancer | |
| KR101245328B1 (en) | Compositions for anticancers containing decursin and/or decursinol angelate, or angelica extract containing decursin and/or decursinol angelate | |
| CN109528731B (en) | Pharmaceutical composition with synergistic effect for treating multiple myeloma and application thereof | |
| JP6895688B2 (en) | New treatments and new treatments for blood cancer | |
| TWI472519B (en) | N-butylidenephthalide-containing pharmaceutical composition for treating liver injury and improving liver function | |
| CN112870366A (en) | New application of EZH2 inhibitor in preparation of tumor treatment drug | |
| CN105663147B (en) | Application of 4-hydroxy salicylanilide in preparation of antitumor drugs | |
| TWI615145B (en) | Antitumor agent containing irinotecan hydrochloride hydrate | |
| WO2021023291A1 (en) | Use of proflavine in treatment of lung cancers | |
| KR20140035974A (en) | Combined pharmaceutical compositions for the treatment of tumours | |
| CN113456819B (en) | Application of OXPHOS inhibitor as antitumor drug Alisertib synergist | |
| UA88884C2 (en) | Kit for the preparation of pharmaceutical composition comprising cis-oxoplatin, pharmaceutical composition and use thereof for the cancer treatment | |
| EP3127544B1 (en) | Anti-tumor drug containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| CN102526012B (en) | Application of retinoic acid and derivatives thereof in preparation of medicines for treating hepatic fibrosis | |
| JP6656484B2 (en) | Radioactive antitumor agent | |
| TWI730019B (en) | Crystallization of thiadiazole derivative DPP-IV inhibitor and its use | |
| US20230151363A1 (en) | Modified short-interfering rna compositions and their use in the treatment of cancer | |
| KR101403112B1 (en) | Peptide for suppression of cancer cell | |
| PODDAR | NEUROBLASTOMA: ROLE OF MICRONUTRIENTS MRINAL KANTI PODDAR, APALA CHAKRABORTY, SOUMYABRATA BANERJEE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |